News

PRRT Nurse's Perspective: What to Expect with PRRT

By Neuroendocrine Cancer Foundation on

UCSF Team at 2022 Multidisciplinary NET Medical Symposium

UCSF representation at the 2022 Multidisciplinary NET Medical Symposium October 27-29 in Washington, D.C.

Claire Mulvey, MD receives Spring 2022 RAP Funding for eNet Study

Claire Mulvey, MD, Assistant Professor of Medicine, UCSF, received funds from the Spring 2022 Research Allocation Project (RAP) for her project "eNET: a Web-Based Health Platform to Investigate Quality of Life in Patients with Neuroendocrine Tumors."

New eNET Study Open

eNET is a study to test the effectiveness of a Web-based program to collect information about symptoms, lifestyle, quality of life, and well-being for patients with neuroendocrine tumors. It is being run by Dr. Emily Bergsland and doctors at UCSF. To learn more or sign up, go to enet.…

NorCal CarciNET Virtual Meeting | Nov 4, 2020

Recording currently unavailable.

Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer

By UroToday.com on
Charles Ryan invites Rahul Aggarwal to discuss treatment-emergent small-cell neuroendocrine prostate cancer, an area not well characterized in the era of modern androgen receptor (AR)-targeting therapy.  

NETRF funds $3.5 million in research to advance neuroendocrine tumor treatment

By Neuroendocrine Tumor Research Foundation (NETRF) on
UCSF's Claire Mulvey, MD, has been awarded a Fellowship Award from the Neuroendocrine Tumor Research Foundation (NETRF) for her project "Trends in incidence and survival outcomes for lung NETs."  The Neuroendocrine Tumor Research Foundation (NETRF), Boston, MA, today announced $3.5 million in…

PET offers more precise screening method to select candidates for radionuclide therapy

By EurekAlert.org on
A new study published in The Journal of Nuclear Medicine evaluated the role of 68Ga-DOTATATE positron emission tomography/computed tomography (PET/CT) in selecting neuroendocrine tumor patients who may benefit from peptide receptor radionuclide therapy (PRRT).

2019 Neuroendocrine Tumor Patient Conference

Presented by the UCSF Helen Diller Family Comprehensive Cancer Center and NorCal CarciNET Community, in collaboration with Stanford University and with generous support provided by supporters and industry partners. Co-Host: NorCal CarciNET Community  Sunday, February 10, 2019 at 8:30am …